SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Monday, June 6, 2016

Naveen Pemmaraju, MD, discusses early results from an ongoing trial of SL-401 in patients with the rare, aggressive malignancy blastic plasmacytoid dendritic cell neoplasm.

December 2018, Volume 4, Issue 14

November 2018, Volume 4, Issue 13

October 2018, Volume 4, Issue 12

Focus on Classical Hematology (Volume 4, Issue 12.1)

SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Recent Articles

Ibrutinib Versus FCR: A “Paradigm Shift” for Younger Patients With Treatment-Naïve CLL

Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism

Ravulizumab: A New Treatment Option for PNH?

A Rapid, Inexpensive Screening Test for Sickle Cell Disease in Uganda

Elotuzumab Combination Prevents Progression from Smoldering to Symptomatic Myeloma

Current Issue

December 2018, Volume 4, Issue 14

Meeting Coverage

How Do Patient and Physician Attitudes Drive Choices in Antiplatelet Therapy for Thrombocytopenia?

CPX-351 Outperforms Induction Chemotherapy in Older High-Risk Patients With AML

Editor`s Corner

My Fair MDs: Encouraging Doctors to Speak Plainly

Draining the Email Swamp